Many people who cease utilizing weight loss drugs will return to their earlier weight within two years, a brand new review of current analysis has discovered.
This charge of weight regain is considerably quicker than that seen in these who have misplaced weight by altering different way of life components, corresponding to weight loss program and train, reasonably than counting on GLP-1 drugs, researchers from the University of Oxford report in a paper revealed Wednesday in The BMJ journal.
GLP-1, which stands for glucagon-like peptide-1, is a hormone naturally made by the physique that helps sign to the mind and the intestine that it’s full and doesn’t must eat any extra.
Weight loss drugs mimic the motion of this hormone by growing the secretion of insulin to decrease blood sugar.
They additionally gradual the motion of meals by the digestive tract, which helps people really feel full extra shortly and for longer, they usually work within the mind to scale back urge for food.
GLP-1 drugs, which embrace Ozempic, Wegovy, Mounjaro and Zepbound, have confirmed to be extremely efficient for weight loss.
However, University of Oxford researchers analyzed the outcomes of 37 research involving greater than 9,300 adults.
They discovered that “weight regain after stopping drugs was faster than after ending behavioural weight loss programmes such as diet and exercise support by approximately 0.3 kg (0.7 pounds) per month,” they stated in a press release.
“This isn’t a failing of the medicines — it reflects the nature of obesity as a chronic, relapsing condition,” stated research lead writer Sam West, a postdoctoral researcher on the Nuffield Department of Primary Care Health Sciences, University of Oxford, within the assertion.
“It sounds a cautionary note for short-term use without a more comprehensive approach to weight management.”
Adam Collins, affiliate professor of vitamin on the University of Surrey in England, who was not concerned within the research, known as the paper “timely and important.”
Collins underlined that weight regain is a standard difficulty in all weight loss interventions, however the paper reveals that this drawback is amplified with GLP-1 drugs.
Collins additionally supplied some attainable explanations as to why that is the case.
“Artificially providing GLP-1 levels several times higher than normal over a long period may cause you to produce less of your own natural GLP-1, and may also make you less sensitive to its effects,” he stated in a press release shared with NCS by the Science Media Centre.
Collins added that this isn’t an issue when taking these drugs, however taking away this supply of GLP-1 then makes overeating “far more likely.”
“Like any addict, going cold turkey is a real challenge. This is further exacerbated if the individual in question has relied solely on GLP-1 to do the heavy lifting during weight loss,” he stated, reasonably than making behavioral adjustments.
Marie Spreckley, weight problems researcher and public well being nutritionist on the University of Cambridge in England, who was not concerned within the research, cautioned that the paper’s long-term conclusions depend on modeled projections, reasonably than noticed information, because the follow-up interval for stopping remedy with newer medicines is proscribed to about 12 months.
“As a result, longer-term statements, including full weight regain within two years, rely on extrapolation beyond the available data,” she stated in a press release shared with NCS by the Science Media Centre, which means that comparisons with behavioral adjustments ought to “be interpreted as suggestive rather than definitive.”
“In real-world terms, the findings reinforce that obesity management typically requires long-term planning. If people stop medication, many are likely to need ongoing nutritional and behavioural support, and health services should anticipate that cardiometabolic benefits may lessen as weight is regained,” Spreckley stated, including that this highlights “the need for further research into effective, scalable strategies for long-term weight maintenance alongside pharmacotherapy.”
GLP-1 drugs have change into extensively used lately, and more than 15 million Americans are actually shedding weight with the drugs.
And a study published in January 2025 advised that widespread GLP-1 drugs authorized for weight loss, diabetes and coronary heart illness might have untapped potential to scale back the dangers of substance abuse issues, psychosis, infections and a few sorts of most cancers and dementia.
However, it is very important keep in mind that utilizing the drugs to suppress urge for food doesn’t simply contribute to fats loss but in addition to decreased muscle mass.
Studies have indicated that wherever between 15% to 60% of the weight people lose is lean muscle mass, which means that these who are utilizing the drugs are suggested to interact in a weekly train routine that features energy coaching to stave off an excessive amount of muscle loss.
It is especially essential for these 65 or older, who are already prone to age-related lack of muscle mass, energy and performance.